Acute Lymphoblastic Leukemia Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Conditions: Hematologic Malignancy; Bone Marrow Transplant Rejection; Acute Myeloid Leukemia (AML); Myelodysplastic Syndromes (MDS); Acute Lymphoblastic Leukemia (ALL), Adult; Multiple Myeloma; Aplastic Anemia; Lymphoma; Non Hodgkin Lymphoma; Hodgkin Lymphoma; Chronic Myeloid Leukemia; Myelofibrosis Interventions: Drug: Darzalex Faspro (Daratumumab and hyaluronidase-fihj); Device: JH-DSA Semi-Quant Screen and Response Score Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Janssen Research& Development, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 3, 2024 Category: Research Source Type: clinical trials

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Conditions: B-cell Acute Lymphoblastic Leukemia; Diffuse Large B-cell Lymphoma; Burkitt Lymphoma; Neuroblastoma; Ewing Sarcoma Interventions: Biological: Zilovertamab vedotin Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 1, 2024 Category: Research Source Type: clinical trials

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
Conditions: Acute Lymphoblastic Leukemia; Non-hodgkin Lymphoma Interventions: Drug: Metabolically Armed CD19 CAR-T cells Sponsors: The Children ' s Hospital of Zhejiang University School of Medicine; Leman Biotech Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 1, 2024 Category: Research Source Type: clinical trials

Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL
Conditions: B-cell Acute Lymphoblastic Leukemia Interventions: Drug: Decitabine, venetoclax and blinatumomab Sponsors: The First Affiliated Hospital of Soochow University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 1, 2024 Category: Research Source Type: clinical trials

Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data
Conditions: Diffuse Large B-cell Lymphoma; Acute Lymphoblastic Leukemia (ALL) Sponsors: Novartis Pharmaceuticals Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 30, 2024 Category: Research Source Type: clinical trials

Observational Study on Invasive Fungal Infection Incidence in Ph-neg Acute Lymphoblastic Leukemia Patients
Conditions: Acute Lymphoblastic Leukemia Sponsors: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 30, 2024 Category: Research Source Type: clinical trials

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
Conditions: T-cell Acute Lymphoblastic Leukemia; T-cell Lymphoma; Mixed Phenotype Acute Leukemia Interventions: Drug: Dexamethasone; Drug: Vincristine; Drug: Daunorubicin; Drug: Calaspargase pegol; Drug: Dasatinib; Drug: Venetoclax; Drug: Bortezomib; Drug: Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine); Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Mercaptopurine; Drug: Nelarabine; Drug: Methotrexate; Drug: Thioguanine Sponsors: St. Jude Children ' s Research Hospital; AbbVie Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 30, 2024 Category: Research Source Type: clinical trials

CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction
Conditions: B-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse; Refractory Acute Lymphoid Leukemia Interventions: Drug: peripheral blood lymphocytes; Drug: CIK cell Sponsors: Beijing GoBroad Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 29, 2024 Category: Research Source Type: clinical trials

Pharmacokinetics of Dexamethasone in Childhood ALL and Reduction in Bone Mineral Density
Conditions: Acute Lymphoblastic Leukemia Sponsors: University of Aarhus Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials

Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)
Conditions: Relapsed or Refractory Acute Lymphoblastic Leukemia; Leukemia Patients With Central Nervous System Infiltration Interventions: Biological: ssCART-19; Drug: Fludarabine; Drug: Cyclophosphamide Sponsors: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd; The First Affiliated Hospital of Soochow University; Peking University People ' s Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials

CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
Conditions: B Lymphocytic Leukemia; B Lymphoblastic Lymphoma Interventions: Device: CAR T cell injection Sponsors: Zhu Xiaofan Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials

Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial
Conditions: Acute Lymphoblastic Leukaemia; Acute Leukemia of Ambiguous Lineage; Chronic Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome; Acute Myeloid Leukemia Interventions: Drug: EBX-102; Drug: Placebo Sponsors: Imperial College London Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials

Early Assessment of Cardiac Function After Treatment With CAR-T Cells
Conditions: Car T- Cell; Hematologic Malignancy; Acute Lymphoblastic Leukemia; Lymphoma, B-Cell; Multiple Myeloma Sponsors: Assistance Publique - H ôpitaux de Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2024 Category: Research Source Type: clinical trials

CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
Conditions: Acute Lymphoblastic Leukemia,B-Cell; Non-hodgkin Lymphoma,B Cell Interventions: Biological: CD19-BAFF Targeted CAR T-cells Sponsors: Zhejiang University; Shanghai YaKe Biotechnology Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials

Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients
Conditions: B-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse; Refractory Acute Lymphoid Leukemia Interventions: Drug: CD19 CAR T-cell; Drug: CD22 CAR T cells; Procedure: hematopoietic stem-cell transplantation Sponsors: Beijing GoBroad Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials